Researcher invents lethal 'lint brush' to capture and kill cancer cells in the bloodstreamDecember 12, 2008In a new tactic in the fight against cancer, Cornell researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body. The strategy, which takes advantage of the body's natural mechanism for fighting infection, could lead to new treatments for a variety of cancers, said King, who is an associate professor of biomedical engineering. In research conducted at the University of Rochester and to be published in an upcoming issue of the journal Biotechnology and Bioengineering, King showed that two naturally occurring proteins can work together to attract and kill as many as 30 percent of tumor cells in the bloodstream -- without harming healthy cells. King's approach uses a tiny tubelike device coated with the proteins that could hypothetically be implanted in a peripheral blood vessel to filter out and destroy free-flowing cancer cells in the bloodstream. To capture the tumor cells in the blood, King used selectin molecules -- proteins that move to the surface of blood vessels in response to infection or injury. Selectin molecules normally recruit white blood cells (leukocytes) which "roll" along their surfaces and create an inflammatory response -- but they also attract cancer cells, which can mimic the adhesion and rolling process. Once the cancer cells adhered to the selectin on the microtube's surface, King exposed them to a protein called TRAIL (for Tumor Necrosis Factor Related Apoptosis-Inducing Ligand), which binds to two so-called "death receptors" on the cancer cells' surface, setting in motion a process that causes the cell to self-destruct. The TRAIL then releases the cells back into the bloodstream to die; and the device is left free to work on new cells. "It's a little more sophisticated than just filtering the blood, because we're not just accumulating cancer cells on the surface," King said. King's research showed that the device can capture and kill about 30 percent of cancer cells flowing past it a single time, with the potential to kill more in the closed-loop system of the body. Used in combination with traditional cancer therapies, King said, the device could remove a significant proportion of metastatic cells, "and give the body a fighting chance to remove the rest of them." The team also showed that a system in which the cancer cells "roll" over the target molecules - presenting their entire surface to the molecules - is four times more effective than a static setup in which the cells and proteins make contact at a single point. King's group tested the device on prostate and colon cancer cells, but noted that it could also be customized with additional peptides or other proteins to target other types of cancer cells. "And if you could reduce or prevent metastasis, pretty much any cancer would be treatable," he said. But translating the research into a clinical application will take time, he added, and is still likely years away. "The actual physical device, when it gets eventually tested in humans, will probably look a lot like an arteriovenous shunt [a small tube, or shunt, that diverts blood flow] with our protein coating," he said. "This has never been tried before. It's a whole new way of approaching cancer treatment," he added. "There's a lot of work yet to be done, of course, before this actually helps people -- but this is how it starts." Other authors on the paper include Kuldeep Rana, a Cornell Ph.D. student, and Jane Liesveld, M.D., a clinician at the University of Rochester. The research was funded by New York state and the National Cancer Institute. Cornell Chronicle |
|||||||||||||||||||||
| Related Cancer Cells Current Events and Cancer Cells News Articles Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Common pain relief medication may encourage cancer growth Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Cancers' Sweet Tooth May Be Weakness The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Paradoxical protein might prevent cancer One difficulty with fighting cancer cells is that they are similar in many respects to the body's stem cells. By focusing on the differences, researchers at Karolinska Institutet have found a new way of tackling colon cancer. The study is presented in the prestigious journal Cell. Cornell researchers identify a weak link in cancer cell armor The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. Researchers 'notch' a victory toward new kind of cancer drug Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. More Cancer Cells Current Events and Cancer Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||